Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance.

Cell death & disease - 13 Oct 2016

Voges Yvonne, Michaelis Martin, Rothweiler Florian, Schaller Torsten, Schneider Constanze, Politt Katharina, Mernberger Marco, Nist Andrea, Stiewe Thorsten, Wass Mark N, Rödel Franz, Cinatl Jindrich

Abstract excerpt

Resistance formation after initial therapy response (acquired resistance) is common in high-risk neuroblastoma patients. YM155 is a drug candidate that was introduced as a survivin suppressant. This mechanism was later challenged, and DNA damage induction and Mcl-1 depletion were suggested instead. Here we investigated the efficacy and mechanism of action of YM155 in neuroblastoma cells with acquired drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B
Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inhibitor of Apoptosis Proteins

Share to Naphthoquinones

Share to Neuroblastoma

Share to Piperazines

Share to Proto-Oncogene Proteins c-mdm2

Share to Survivin

Source

Open in PubMed Open full text

Identifiers

PMID: 27735941
DOI: 10.1038/cddis.2016.257
PMCID: PMC5133961

Genes

ABCB1
MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance.PMID 27735941Read ↗

Testing of the survivin suppressant YM155 in a large panel of drug-resistant neuroblastoma cell linesSemantic proximity Read ↗

Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastomaSemantic proximity Read ↗

Identification of miRNAs contributing to neuroblastoma chemoresistanceSemantic proximity Read ↗

YM155 inhibits neuroblastoma growth through degradation of MYCN: A new role as a USP7 inhibitorSemantic proximity Read ↗

YM155 Induces DNA Damage and Cell Death in Anaplastic Thyroid Cancer Cells by Inhibiting DNA Topoisomerase IIα at the ATP-Binding SiteSemantic proximity Read ↗

Overcome Resistance in Doxorubicin-Adapted Hodgkin Lymphoma Cells With Acquired Multidrug Resistance and Improved Immunosuppressive AbilitiesSemantic proximity Read ↗

YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathwaySemantic proximity Read ↗

Mechanism of Drug Resistance to First-Line Chemotherapeutics Mediated by TXNDC17 in Neuroblastomas.Semantic proximity Read ↗

Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy.Semantic proximity Read ↗

Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents.Semantic proximity Read ↗

p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma.Semantic proximity Read ↗

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.